Plavix

E561776

Plavix is a widely used prescription antiplatelet medication (clopidogrel) that helps prevent blood clots and reduce the risk of heart attack and stroke.

Try in SPARQL Jump to: Statements Referenced by

Statements (51)

Predicate Object
instanceOf P2Y12 inhibitor
antiplatelet medication
brand name drug
pharmaceutical drug
affects platelet function
approvedBy U.S. Food and Drug Administration NERFINISHED
coMarketedBy Bristol-Myers Squibb NERFINISHED
contraindication active pathological bleeding
severe hepatic impairment
developedBy Sanofi NERFINISHED
doesNotAffect coagulation factors directly
hasActiveIngredient clopidogrel bisulfate
hasATCCode B01AC04
hasBlackBoxWarning reduced effectiveness in CYP2C19 poor metabolizers
hasCommonDrugInteraction esomeprazole NERFINISHED
omeprazole
hasDosageForm film-coated tablet
hasDrugClass thienopyridine
hasDurationOfEffect platelet inhibition lasts for platelet lifespan
hasEffect inhibits platelet aggregation
reduces blood clot formation
hasFDAApprovalYear 1997
hasGenericName clopidogrel
hasLegalStatusEU prescription only
hasLegalStatusUS prescription only
hasMechanismOfAction irreversible inhibition of platelet P2Y12 ADP receptor
hasOnsetOfAction within hours after loading dose
hasRouteOfAdministration oral
hasTypicalStrength 300 mg tablet
75 mg tablet
isPrescriptionOnly true
isProdrug true
majorAdverseEffect bleeding
gastrointestinal bleeding
thrombocytopenia
metabolizedBy CYP2C19 NERFINISHED
CYP3A4
oftenUsedWith aspirin
pregnancyCategoryUS B
rareAdverseEffect thrombotic thrombocytopenic purpura
reducesRiskOf heart attack
stroke
vascular death
requires hepatic bioactivation
takenHowOften once daily
usedFor acute coronary syndrome
management of peripheral arterial disease
prevention of atherothrombotic events
prevention of stent thrombosis
secondary prevention of ischemic stroke
secondary prevention of myocardial infarction

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Sanofi hasBrand Plavix